Study Description: The purpose of this study is to evaluate how effective Human Globulin (IGIV-C) is in reducing the dose of corticosteroids in subjects with myasthenia gravis (MG). Study drug infusions will be given every 3 weeks and subjects will be followed closely for side effects and changes in their condition.
Principal Investigator: Michael Rivner
Eligibility Criteria: Patients may be eligible for this study if: anti-acetylcholine receptor (AChR) antibody positive. confirmed diagnosis of generalized MG must be on a stable dose of corticosteroids (CS) for the treatment of MG and had at least one previous attempt to taper down CS doses. Patients may not be eligible for this study if: Taking cyclophosphamide or any other immunosuppressive agent apart from the ones allowed in this study Recent thymectomy, myasthenic crisis, reactions, to IGIV, or use of anti-coagulant medications The use of certain MG medications (such as Rituximab, recent plasma exchange, recent IGIV, eculizumab, etc.) can be exclusionary so contact the study staff if you have questions regarding excluded medications Any other unstable medical conditions including recent heart attack or stroke
Compensation: Yes, subjects will be compensated.
Compensation Explanation: Subjects will be paid $50 travel subsistence for each completed visit
If you don't see specific studies that interest you, please submit your contact information for future studies.